Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;155(3):291-9.
doi: 10.1038/bjp.2008.284. Epub 2008 Jul 7.

Novel long-acting bronchodilators for COPD and asthma

M Cazzola  1 , M G Matera
Affiliations
Review

Novel long-acting bronchodilators for COPD and asthma

M Cazzola et al. Br J Pharmacol. 2008 Oct.

Abstract

An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control. Therefore, the incorporation of once-daily dose administration is an important strategy to improve adherence and is a regimen preferred by most patients, which may also lead to enhancement of compliance, and may have advantages leading to improved overall clinical outcomes. Once-daily beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as carmoterol, indacaterol, GSK-159797, GSK-597901, GSK-159802, GSK-642444 and GSK-678007 are under development for the treatment of asthma and COPD. Also some new long-acting antimuscarinic agents (LAMAs) such as aclidinium, LAS-35201, GSK656398, GSK233705, NVA-237 (glycopyrrolate) and OrM3 are under development. In any case, the current opinion is that it will be advantageous to develop inhalers containing combination of several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimens as much as possible. Consequently, several options for once-daily dual-action ultra LABA+LAMA combination products are currently being evaluated. A different approach is to have a dimer molecule in which both pharmacologies are present (these molecules are known as M3 antagonist-beta2 agonist (MABA) bronchodilators). The advent of a successful MABA product will revolutionize the field and open the door for a new range of combination products.

PubMed Disclaimer

References

    1. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555. - PubMed
    1. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther. 2007;20:290–303. - PubMed
    1. Anonymous Theravance, Inc. (THRX) Announces Positive Results of Clinical Program in Beyond Advair Collaboration 2007. Available at:Accessed 27 December 2007
    1. Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al. Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients. Eur Respir J. 2006;28:430s.
    1. Aubier M, Duval X, Knight H, Perry S, Majumdar T, Kaiser G, et al. Indacaterol, a novel once-daily β2-agonist, is effective and well tolerated on multiple dosing in patients with mild-to-moderate COPD. Eur Respir J. 2005;26:287s.

Publication types

MeSH terms